Apogee Therapeutics (APGE) Net Equity Issued and Repurchased (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $378.2 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $378.2 million in Q1 2026; TTM through Mar 2026 was $465.8 million, a 950.0% increase from a year earlier, with the FY2025 full-year figure at $67.6 million, down 84.98% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $378.2 million, up from $67.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for APGE reached as high as $450.5 million in Q1 2024 and fell as low as -$541000.0 in Q2 2024.
• Historically, Net Equity Issued and Repurchased has averaged $137.2 million across 4 years, with a median of $44.9 million in 2024.
• Across the five-year window, Net Equity Issued and Repurchased jumped 21179.81% in 2024 and soared 50.56% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at -$213000.0 in 2023, then soared by 21179.81% to $44.9 million in 2024, then jumped by 50.56% to $67.6 million in 2025, then jumped by 459.42% to $378.2 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $378.2 million in Q1 2026, $67.6 million in Q4 2025, and $20.0 million in Q3 2025.